 |
 |
 |
 |
|
|||||
|
|
ECONOMICS AND REIMBURSEMENT RESEARCH Economic Clinical Trials: Clinical trials designed specifically to assess the economic impact of one or more treatments when used to treat a specific medical condition. Economic Modeling: Development of cost of illness, cost-effectiveness, cost-consequence, cost-utility, and disease models to assess the economic impact of new and existing products, support development decisions, and identify target patient sub-groups. Claims Data Analysis: The use of medical and pharmacy claims data to assess health resource utilization and consequently the financial impact of alternative treatment options. NICE (UK) and AMCP Submissions: Development of dossiers summarizing relevant epidemiological, clinical, and health economics data on new or existing bio-pharmaceutical products in compliance with the submission formats specified by NICE and AMCP. Budget Impact Computer Models: Development of user-friendly computer models that can identify the potential financial impact of adding new or existing bio-pharmaceutical products to managed care, hospital, third party payor, and government formularies. Payor Research: Assessment of payor information needs, attitudes towards, and factors influencing the adoption of new treatments and/or indications. Reimbursement Reviews: Review and analysis of government and third party reimbursement policies and development of strategies to ensure maximum coverage from all payors for clients’ products. Policy Analysis: Analysis of the business impact of current
and impending health care legislation on the pharmaceutical and biotechnology
industries. Competitor Reviews: In-depth analyses of strengths and weaknesses of competitor health economics studies and promotional claims. Opportunity Assessments: Assessment of the efficacy and safety
profiles of client and competitor products, disease epidemiology,
and market trends, and identification of the types of economic assessments
key to support market access.
|
||||||||